The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Bristol-Myers Squibb is warning against the use of the antibiotic drug Tequin in diabetic patients after reports of several fatalities, the U.S. Food and Drug Administration said recently.

According to the FDA, the company is adding a contraindication warning for diabetics to the drug’s label as well as strengthening its warning that Tequin can cause both low and high blood sugar levels in patients. The label will include warnings that patients who are older, have renal insufficiency and take other medicine that affects glucose levels can also be at risk, according to the agency.

Comments are closed.

Of Interest